Logo
ScienceStack
Table of Contents
Fetching ...
Sign In

Molecular Communication-Based Intelligent Dopamine Rate Modulator for Parkinson's Disease Treatment

Elham Baradari and, Ozgur B Akan

TL;DR

This paper proposes a molecular communication–driven strategy to treat Parkinson's disease by injecting an Intelligent Dopamine Rate Modulator (IDRM) between the SNc and striatum to restore dopaminergic signaling. The IDRM architecture combines a dopamine storage unit, a dopamine-release mechanism, and a dopamine-sensing system that activates release in response to endogenous cues, enabling targeted exogenous dopamine delivery while limiting off-target effects. It models the pharmacokinetics of delivering a dopamine compound (DAC) from oral intake through the GI tract, plasma, BBB crossing, and diffusion in the brain extracellular matrix, using transfer functions and a diffusion framework to estimate DAC availability at the IDRM. Numerical results, calibrated on Levodopa data, demonstrate plausible pathways for loading the IDRM with dopamine and delivering sufficient dopamine to the basal ganglia, supporting a targeted, root-cause–oriented PD therapy with potential for reduced systemic side effects. Overall, the work highlights a feasible MC-based route to local dopamine replenishment in PD and sets the stage for experimental validation of IDRM-enabled nano-biomedical therapies.

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disease, and it is caused by the loss of dopaminergic neurons in the basal ganglia (BG). Currently, there is no definite cure for PD, and available treatments mainly aim to alleviate its symptoms. Due to impaired neurotransmitter-based information transmission in PD, molecular communication-based approaches can be employed as potential solutions to address this issue. Molecular Communications (MC) is a bio-inspired communication method utilizing molecules for carrying information. This mode of communication stands out for developing bio-compatible nanomachines for diagnosing and treating, particularly in addressing neurodegenerative diseases like PD, due to its compatibility with biological systems. This study presents a novel treatment method that introduces an Intelligent Dopamine Rate Modulator (IDRM), which is located in the synaptic gap between the substantia nigra pars compacta (SNc) and striatum to compensate for insufficiency dopamine release in BG caused by PD. For storing dopamine in the IDRM, dopamine compound (DAC) is swallowed and crossed through the digestive system, blood circulatory system, blood-brain barrier (BBB), and brain extracellular matrix uptakes with IDRMs. Here, the DAC concentration is calculated in these regions, revealing that the required exogenous dopamine consistently reaches IDRM. Therefore, the perpetual dopamine insufficiency in BG associated with PD can be compensated. This method reduces drug side effects because dopamine is not released in other brain regions. Unlike other treatments, this approach targets the root cause of PD rather than just reducing symptoms.

Molecular Communication-Based Intelligent Dopamine Rate Modulator for Parkinson's Disease Treatment

TL;DR

This paper proposes a molecular communication–driven strategy to treat Parkinson's disease by injecting an Intelligent Dopamine Rate Modulator (IDRM) between the SNc and striatum to restore dopaminergic signaling. The IDRM architecture combines a dopamine storage unit, a dopamine-release mechanism, and a dopamine-sensing system that activates release in response to endogenous cues, enabling targeted exogenous dopamine delivery while limiting off-target effects. It models the pharmacokinetics of delivering a dopamine compound (DAC) from oral intake through the GI tract, plasma, BBB crossing, and diffusion in the brain extracellular matrix, using transfer functions and a diffusion framework to estimate DAC availability at the IDRM. Numerical results, calibrated on Levodopa data, demonstrate plausible pathways for loading the IDRM with dopamine and delivering sufficient dopamine to the basal ganglia, supporting a targeted, root-cause–oriented PD therapy with potential for reduced systemic side effects. Overall, the work highlights a feasible MC-based route to local dopamine replenishment in PD and sets the stage for experimental validation of IDRM-enabled nano-biomedical therapies.

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disease, and it is caused by the loss of dopaminergic neurons in the basal ganglia (BG). Currently, there is no definite cure for PD, and available treatments mainly aim to alleviate its symptoms. Due to impaired neurotransmitter-based information transmission in PD, molecular communication-based approaches can be employed as potential solutions to address this issue. Molecular Communications (MC) is a bio-inspired communication method utilizing molecules for carrying information. This mode of communication stands out for developing bio-compatible nanomachines for diagnosing and treating, particularly in addressing neurodegenerative diseases like PD, due to its compatibility with biological systems. This study presents a novel treatment method that introduces an Intelligent Dopamine Rate Modulator (IDRM), which is located in the synaptic gap between the substantia nigra pars compacta (SNc) and striatum to compensate for insufficiency dopamine release in BG caused by PD. For storing dopamine in the IDRM, dopamine compound (DAC) is swallowed and crossed through the digestive system, blood circulatory system, blood-brain barrier (BBB), and brain extracellular matrix uptakes with IDRMs. Here, the DAC concentration is calculated in these regions, revealing that the required exogenous dopamine consistently reaches IDRM. Therefore, the perpetual dopamine insufficiency in BG associated with PD can be compensated. This method reduces drug side effects because dopamine is not released in other brain regions. Unlike other treatments, this approach targets the root cause of PD rather than just reducing symptoms.
Paper Structure (14 sections, 10 equations, 9 figures, 1 table)

This paper contains 14 sections, 10 equations, 9 figures, 1 table.

Table of Contents

  1. Introduction
  2. Physiological Background
  3. designing Intelligent Dopamine Rate Modulator for Parkinson’s disease treatment
  4. Dopamine Release System
  5. Dopamine Sensor
  6. Intelligent Dopamine-releasing
  7. Dopamine Storage
  8. IDRM Receiver Types: The Passive and Absorbing Receivers
  9. Delivering Dopamine Compound to the storage part of Intelligent rate Dopamine Modulator
  10. DAC concentration in plasma level
  11. DAC concentration in blood circulation system
  12. DAC concentration across the Blood-Brain Barrier
  13. DAC propagation in the extracellular matrix of the brain
  14. Numerical results

Figures (9)

  • Figure 1: Basal Ganglia (BG) Pathways: Direct and Indirect Routes, along with Neuronal Connections and Neurotransmitters haeri2005modeling.
  • Figure 2: Dopamine levels in three different states: a) Healthy state, b) PD state, and c) Hypothesis regarding IDRMs for alleviating the PD state.
  • Figure 3: Proposed Receivers for IDRMs.
  • Figure 4: DDS components for transferring DAC to IDRMs.
  • Figure 5: Blood plasma level of Levodopa during the timehacisalihzade1989optimization.
  • ...and 4 more figures